Zacks Investment Research cut shares of Imperva Inc. (NYSE:IMPV) from a buy rating to a hold rating in a report released on Tuesday.

According to Zacks, “Imperva Inc. is engaged in the development of protection software and services for business applications and databases. The Company delivers innovative technology to give full audit accountability and separation of duties to meet regulatory compliance. It offers SecureSphere Data Security Suite to protect sensitive data from hackers and malicious insiders along with providing a fast and cost-effective route to regulatory compliance and establishes a repeatable process for data risk management. The Company’s SecureSphere offers database security solutions to secure sensitive data stored in databases, File Security solutions to protect sensitive files on file servers, storage devices, content repositories, and meet regulatory compliance mandates and Web Application Security solutions to protect web applications from cyber attacks. Imperva Inc. is headquartered in Redwood Shores, California. “

Other analysts have also recently issued research reports about the stock. Evercore ISI raised shares of Imperva from a hold rating to a buy rating in a research note on Friday, November 4th. DA Davidson raised shares of Imperva from a neutral rating to a buy rating and boosted their target price for the stock from $55.00 to $57.00 in a research note on Friday, November 4th. Needham & Company LLC raised shares of Imperva from a hold rating to a buy rating and decreased their target price for the stock from $64.00 to $43.00 in a research note on Friday, November 4th. Wunderlich initiated coverage on shares of Imperva in a research note on Tuesday, September 13th. They set a hold rating and a $50.00 target price on the stock. Finally, Deutsche Bank AG reaffirmed a hold rating on shares of Imperva in a research note on Saturday, October 15th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and thirteen have given a buy rating to the company’s stock. The stock has a consensus rating of Buy and an average price target of $49.50.

Imperva (NYSE:IMPV) traded up 0.690% during mid-day trading on Tuesday, hitting $40.125. 109,079 shares of the company were exchanged. Imperva has a 12-month low of $31.11 and a 12-month high of $62.49. The company’s 50-day moving average is $38.28 and its 200 day moving average is $43.38. The company’s market capitalization is $1.32 billion.

Imperva (NYSE:IMPV) last announced its quarterly earnings data on Thursday, November 3rd. The company reported $0.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.24. The business had revenue of $68.40 million for the quarter, compared to analysts’ expectations of $63.10 million. Imperva had a negative net margin of 25.60% and a negative return on equity of 28.37%. The firm’s quarterly revenue was up 8.0% compared to the same quarter last year. During the same period last year, the firm posted $0.19 earnings per share. Analysts expect that Imperva will post ($0.37) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Imperva Inc. (IMPV) Downgraded by Zacks Investment Research” was originally reported by Watch List News and is the propert of of Watch List News. If you are accessing this news story on another site, it was illegally stolen and republished in violation of US and international copyright and trademark legislation. The correct version of this news story can be read at http://www.watchlistnews.com/imperva-inc-impv-downgraded-by-zacks-investment-research/1059981.html.

In other news, SVP Mark E. Kraynak sold 3,332 shares of the business’s stock in a transaction dated Wednesday, November 16th. The shares were sold at an average price of $40.16, for a total transaction of $133,813.12. Following the completion of the sale, the senior vice president now directly owns 448 shares of the company’s stock, valued at $17,991.68. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Amichai Shulman sold 3,085 shares of the business’s stock in a transaction dated Tuesday, November 15th. The stock was sold at an average price of $40.10, for a total transaction of $123,708.50. Following the sale, the insider now directly owns 92,000 shares of the company’s stock, valued at $3,689,200. The disclosure for this sale can be found here. 2.20% of the stock is currently owned by company insiders.

Several large investors have recently bought and sold shares of IMPV. Credit Suisse AG increased its stake in shares of Imperva by 865.9% in the second quarter. Credit Suisse AG now owns 1,431,447 shares of the company’s stock worth $61,568,000 after buying an additional 1,283,243 shares during the last quarter. Litespeed Management L.L.C. increased its stake in shares of Imperva by 893.6% in the third quarter. Litespeed Management L.L.C. now owns 943,915 shares of the company’s stock worth $50,698,000 after buying an additional 848,915 shares during the last quarter. Pictet Asset Management Ltd. increased its stake in shares of Imperva by 50.6% in the second quarter. Pictet Asset Management Ltd. now owns 804,552 shares of the company’s stock worth $30,718,000 after buying an additional 270,312 shares during the last quarter. FIL Ltd purchased a new stake in shares of Imperva during the second quarter worth about $10,170,000. Finally, Jet Capital Investors L P purchased a new stake in shares of Imperva during the second quarter worth about $9,670,000. 92.72% of the stock is owned by institutional investors.

Imperva Company Profile

Imperva, Inc provides cyber-security solutions that protect business-critical data and applications whether in the cloud or on premises. The Company operates in the segment of development, marketing, sales, service and support of cyber-security solutions that protect business critical data and applications whether in the cloud or on premises.

5 Day Chart for NYSE:IMPV

Get a free copy of the Zacks research report on Imperva (IMPV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Imperva Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imperva Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.